Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | USP19 | O94966 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3179511 | 0.82 | CYP11B1 (0.46) | NPC1IL4I1CYP11B1CYP11B2 | |
| Trifluoroacetic Acid SCHEMBL3169897 | 0.81 | NAAA (0.49) | NPC1TDP1NAAAGRIN2BC3AR1 | |
| SCHEMBL3164361 | 0.81 | CYP11B1 (0.52) | IL4I1CYP11B1CYP11B2 | |
| Trifluoroacetic Acid SCHEMBL3174133 | 0.80 | GRIN2B (0.46) | NPC1GRIN2BRAB9A | |
| Trifluoroacetic Acid SCHEMBL3169886 | 0.80 | PDK2 (0.51) | NPC1KMT2AGRIN2BRAB9A | |
| Trifluoroacetic Acid SCHEMBL3173659 | 0.80 | ACE (0.46) | RAB9AIL4I1 | |
| Trifluoroacetic Acid SCHEMBL3170072 | 0.79 | DCK (0.48) | NPC1TDP1NAAAKMT2AC3AR1 | |
| SCHEMBL3163787 | 0.75 | KDM4E (0.45) | NPC1RAB9AIL4I1CYP11B1CYP11B2 | |
| SCHEMBL3179376 | 0.75 | CYP11B1 (0.51) | NPC1IL4I1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL3184100 | 0.74 | CYP11B1 (0.50) | NPC1USP19IL4I1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188291-B2 | Heteroaryl-substituted carboxamides and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2097382-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | Sanofi-Aventis (FR) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077507-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939181-A1 | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | TBXAS1, PTGIS, NOS2 | NPC1 2911/4885TDP1 1551/4885NAAA 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.